Compare Merck & Co., Inc. (MRK) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Global X Uranium ETF — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Global X Uranium ETF trades at $38.79 (market cap $5.48B). The key difference: Merck & Co., Inc. is far larger — about 64.1× Global X Uranium ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Global X Uranium ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Global X Uranium ETF for 62 Days on average.
| MRK | URA | |
|---|---|---|
Market Cap | $351.28B | $5.48B |
Volume | 7,969,665 | 5,287,170 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $156.43 | $61.81 |
52-Week Low | $82.49 | $37.52 |
Typical Hold Time | 98 Days | 62 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
URA (Global X Uranium ETF) trades at $38.90, down 2.58% with a bearish technical signal. The ETF faces pressure from recent uranium sector volatility despite positive long-term nuclear energy demand drivers. Key support levels cluster around $37-38 while resistance sits at $39-41. Recent news highlights both opportunities from AI power demand growth and risks from sector-specific headwinds.
The uranium sector faces near-term volatility but benefits from structural tailwinds including AI power demand and global nuclear expansion. Investment opportunities exist through diversified uranium exposure, though risks include commodity price sensitivity and regulatory uncertainty. Current technical weakness suggests cautious entry points may emerge near support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
